Cadila Healthcare Limited has informed the Exchange regarding a press release dated October 08, 2021, titled "Fortress Biotech and Cyprium Therapeutics with support from its licensing partner Sentynl Therapeutics, Inc. a wholly owned subsidiary of Cadila Healthcare Limited ( Zydus ) Announce Positive Clinical Data for CUTX-101, Copper Histidinate for the treatment of Menkes Disease".